Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 898-900, 2005. First published February 3, 2005; 10.1373/clinchem.2004.047167
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
clinchem.2004.047167v1
51/5/898    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, D.
Right arrow Articles by Gelb, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, D.
Right arrow Articles by Gelb, M. H.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2005;51:898-900.)
© 2005 American Association for Clinical Chemistry, Inc.

Technical Briefs

Tandem Mass Spectrometric Analysis of Dried Blood Spots for Screening of Mucopolysaccharidosis I in Newborns

Ding Wang1, Bhramara Eadala1, Martin Sadilek1, Nestor A. Chamoles2, Frantisek Turecek1, C. Ronald Scott3 and Michael H. Gelb1,4,a

Departments of1 Chemistry, 3 Pediatrics, and 4 Biochemistry, University of Washington, Seattle, WA; 2 Laboratory of Neurochemistry, Buenos Aires, Argentina;

aaddress correspondence to this author at: Departments of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195; fax 206-685-8665, e-mail gelb@chem.washington.edu

The first 300 words of the full text of this article appear below.

Mucopolysaccharidosis type I (MPS-I), caused by a deficiency of {alpha}-L-iduronidase (IDUA; EC 3.2.1.76) activity, can manifest as three major phenotypes, usually defined by clinical criteria: Hurler (severe), Scheie (mild), and Hurler–Scheie (intermediate) syndromes.

IDUA is crucial for degradation of glycosaminoglycans such as dermatan and heparan sulfate. Failure to break down these polysaccharides causes physical changes such as joint stiffness, skeletal abnormalities, and corneal clouding. Hurler syndrome is characterized by valvular heart disease, mental deterioration, and death in childhood. Enzyme replacement therapy has been developed for MPS-I, and bone marrow transplantation is beneficial if performed early (1). Because early detection is necessary for optimum clinical response to therapy, the need for newborn screening of MPS-I is under active discussion.

Lysosomal enzymes can be measured in rehydrated dried blood spots (DBS) (2)(3)(4)(5)(6)(7)(8). Fluorometric, radiometric, and electrospray ionization tandem mass spectrometry (ESI-MS/MS) assays have been developed. The latter offer the capability of assaying the products of several enzymes simultaneously (multiplexing) (8). In this report, we describe an ESI-MS/MS assay that directly measures the reaction velocity of IDUA in rehydrated DBS for the newborn screening of MPS-I. We also show that the assay can be combined with ESI-MS/MS assays of Niemann–Pick type A/B, Krabbe, Gaucher, Pompe, and Fabry diseases (8) for the simultaneous analysis of six lysosomal storage diseases.

All experiments with DBS were conducted in compliance with Institutional Review Board review. All MPS-I-affected patients had been diagnosed previously with established clinical and biochemical procedures. DBS were kept at ambient temperature during shipment (<10 days) and then stored at –20 °C in zip-lock plastic bags (one bag sealed inside of a second bag). Zip-lock bags were kept in a sealed plastic . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
S. Blanchard, M. Sadilek, C. R. Scott, F. Turecek, and M. H. Gelb
Tandem Mass Spectrometry for the Direct Assay of Lysosomal Enzymes in Dried Blood Spots: Application to Screening Newborns for Mucopolysaccharidosis I
Clin. Chem., December 1, 2008; 54(12): 2067 - 2070.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. Wang, T. Wood, M. Sadilek, C. R. Scott, F. Turecek, and M. H. Gelb
Tandem Mass Spectrometry for the Direct Assay of Enzymes in Dried Blood Spots: Application to Newborn Screening for Mucopolysaccharidosis II (Hunter Disease)
Clin. Chem., January 1, 2007; 53(1): 137 - 140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
E. Parkinson-Lawrence, M. Fuller, J. J. Hopwood, P. J. Meikle, and D. A. Brooks
Immunochemistry of Lysosomal Storage Disorders
Clin. Chem., September 1, 2006; 52(9): 1660 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. S. Millington
Newborn Screening for Lysosomal Storage Disorders
Clin. Chem., May 1, 2005; 51(5): 808 - 809.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.